USE OF THE GLOBULAR DOMAIN OF ACRP30 FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF THROMBOSIS-RELATED DISEASES
It is the object of the present invention to provide novel means for the treatment and/or prevention of thrombosis, tumor implantation, tumor seeding and metastasis. More specifically, the present invention relates to the use of a polypeptide comprising the globular head of Acrp30 for the manufacture of a medicament for treatment and/or prevention of thrombosis-related disorder, an hypertensive disorder of the pregnancy, tumor implantation, tumor seeding and metastasis.
1 - 17 . (canceled)
18 . A method of treating tumor seeding, metastasis or tumor implantation in a subject comprising the administration of a composition comprising an Acrp30g polypeptide or of an agonist thereof to said subject, wherein said Acrp30g polypeptide is selected from:
a) a polypeptide comprising amino acids 114 to 244 of SEQ ID NO: 1;
b) a polypeptide comprising SEQ ID NO: 2;
c) a polypeptide comprising SEQ ID NO: 3;
d) a polypeptide comprising amino acids 106 to 244 of SEQ ID NO: 1; or
e) a polypeptide comprising amino acids 79 to 244 of SEQ ID NO: 1;
and wherein said Acrp30g polypeptide does not comprise amino acids 1 to 70 of SEQ ID NO: 1; and
said Acrp30g polypeptide has an anti-coagulant and/or an anti-aggregant activity on platelets.
19 . The method according to claim 18 , wherein said Acrp30g polypeptide is PEGylated.
20 . The method according to claim 18 , wherein said Acrp30g polypeptide is a fused protein comprising a carrier molecule.
21 . The method according to claim 20 , wherein said Acrp30g polypeptide is a fused protein comprising an immunoglobulin (Ig) domain.
22 . The method according to claim 18 , wherein an anti-coagulant and/or anti-aggregant agent different from said Acrp30g polypeptide is simultaneously, sequentially, or separately administered.
23 . The method according to claim 18 , wherein a fibrinolytic agent is simultaneously, sequentially, or separately administered.
24 . The method according to claim 18 , wherein a drug for the treatment of cancer is simultaneously, sequentially, or separately administered.
25 . A method of treating deep vein thrombosis (DVT), pulmonary embolism (PE), chronic venous insufficiency (CVI), thrombophlebitis or postphlebitic syndrome comprising the administration of a composition comprising an Acrp30g polypeptide or of an agonist thereof to said subject, wherein said Acrp30g polypeptide is selected from:
a) a polypeptide comprising amino acids 114 to 244 of SEQ ID NO: 1;
b) a polypeptide comprising SEQ ID NO: 2;
c) a polypeptide comprising SEQ ID NO: 3;
d) a polypeptide comprising amino acids 106 to 244 of SEQ ID NO: 1; or
e) a polypeptide comprising amino acids 79 to 244 of SEQ ID NO: 1;
and wherein said Acrp30g polypeptide does not comprise amino acids 1 to 70 of SEQ ID NO: 1; and
said Acrp30g polypeptide has an anti-coagulant and/or an anti-aggregant activity on platelets.
26 . The method according to claim 25 , wherein said Acrp30g polypeptide is PEGylated.
27 . The method according to claim 25 , wherein said Acrp30g polypeptide is a fused protein comprising a carrier molecule.
28 . The method according to claim 27 , wherein said Acrp30 polypeptide is a fused protein comprising an immunoglobulin (Ig) domain.
29 . The method according to claim 25 , wherein an anti-coagulant and/or anti-aggregant agent different from said Acrp30g polypeptide is simultaneously, sequentially, or separately administered.
30 . The method according to claim 25 , wherein a fibrinolytic agent is simultaneously, sequentially, or separately administered.
31 . The method according to claim 25 , wherein a drug for the treatment of cancer is simultaneously, sequentially, or separately administered.
32 . A method of treating a hypertensive disorder of the pregnancy comprising the administration of a composition comprising an Acrp30g polypeptide or of an agonist thereof to said subject, wherein said Acrp30g polypeptide is selected from:
a) a polypeptide comprising amino acids 114 to 244 of SEQ ID NO: 1;
b) a polypeptide comprising SEQ ID NO: 2;
c) a polypeptide comprising SEQ ID NO: 3;
d) a polypeptide comprising amino acids 106 to 244 of SEQ ID NO: 1; or
e) a polypeptide comprising amino acids 79 to 244 of SEQ ID NO: 1;
and wherein said Acrp30g polypeptide does not comprise amino acids 1 to 70 of SEQ ID NO: 1; and
said Acrp30g polypeptide has an anti-coagulant and/or an anti-aggregant activity on platelets.
33 . A method of treating coronary arterial thrombosis, ischemic stroke, intermittent claudication or atrial fibrillation comprising the administration of a composition comprising an Acrp30g polypeptide or of an agonist thereof to said subject, wherein said Acrp30g polypeptide is selected from:
a) a polypeptide comprising amino acids 114 to 244 of SEQ ID NO: 1;
b) a polypeptide comprising SEQ ID NO: 2;
c) a polypeptide comprising SEQ ID NO: 3;
d) a polypeptide comprising amino acids 106 to 244 of SEQ ID NO: 1; or
e) a polypeptide comprising amino acids 79 to 244 of SEQ ID NO: 1;
and wherein said Acrp30g polypeptide does not comprise amino acids 1 to 70 of SEQ ID NO: 1; and
said Acrp30g polypeptide has an anti-coagulant and/or an anti-aggregant activity on platelets.
34 . A method of treating arterio-veinous shunts, disseminated intravascular coagulation and tlhrombophilia comprising the administration of a composition comprising an Acrp30g polypeptide or of an agonist thereof to said subject, wherein said Acrp30g polypeptide is selected from:
a) a polypeptide comprising amino acids 114 to 244 of SEQ ID NO: 1;
b) a polypeptide comprising SEQ ID NO: 2;
c) a polypeptide comprising SEQ ID NO: 3;
d) a polypeptide comprising amino acids 106 to 244 of SEQ ID NO: 1; or
e) a polypeptide comprising amino acids 79 to 244 of SEQ ID NO: 1;
and wherein said Acrp30g polypeptide does not comprise amino acids 1 to 70 of SEQ ID NO: 1; and
said Acrp30g polypeptide has an anti-coagulant and/or an anti-aggregant activity on platelets.
35 . A method of treating melanomas, leukemias, lymphomas, myelomas or carcinomas comprising the administration of a composition comprising an Acrp30g polypeptide or of an agonist thereof to said subject, wherein said Acrp30g polypeptide is selected from:
a) a polypeptide comprising amino acids 114 to 244 of SEQ ID NO: 1;
b) a polypeptide comprising SEQ ID NO: 2;
c) a polypeptide comprising SEQ ID NO: 3;
d) a polypeptide comprising amino acids 106 to 244 of SEQ ID NO: 1; or
e) a polypeptide comprising amino acids 79 to 244 of SEQ ID NO: 1;
and wherein said Acrp30g polypeptide does not comprise amino acids 1 to 70 of SEQ ID NO: 1; and
said Acrp30g polypeptide has an anti-coagulant and/or an anti-aggregant activity on platelets.